Inmolecule Nanotech (XPAR:MLINA) Liabilities-to-Assets : 0.39 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
7 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Liabilities-to-Assets?

Inmolecule Nanotech XPAR:MLINA 7 Liabilities-to-Assets is 0.39 as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 7/100. The stock has 2 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Inmolecule Nanotech's Total Liabilities for the quarter that ended in Dec. 2024 was €4.85 Mil. Inmolecule Nanotech's Total Assets for the quarter that ended in Dec. 2024 was €12.30 Mil. Therefore, Inmolecule Nanotech's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.39.

Inmolecule Nanotech  (XPAR:MLINA) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Inmolecule Nanotech Liabilities-to-Assets Related Terms

Inmolecule Nanotech Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Liabilities-to-Assets Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Liabilities-to-Assets
0.40 0.39

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
Liabilities-to-Assets 0.40 0.39

XPAR:MLINA vs VRTX, REGN, RVMD: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inmolecule Nanotech Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's Liabilities-to-Assets falls into.


XPAR:MLINA
7GF Score
Inmolecule Nanotech SA XPAR:MLINA
Liabilities-to-Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Inmolecule Nanotech's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=4.845/12.303
=0.39

Inmolecule Nanotech's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=4.845/12.303
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.39 mean?
Inmolecule Nanotech (XPAR:MLINA) has a Liabilities-to-Assets of 0.39 as of Dec. 2024. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Inmolecule Nanotech and its competitors.
Is Inmolecule Nanotech's Liabilities-to-Assets too high?
Inmolecule Nanotech's current Liabilities-to-Assets is 0.39. Overall, Inmolecule Nanotech has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Liabilities-to-Assets compare to VRTX and REGN?
Inmolecule Nanotech's Liabilities-to-Assets of 0.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current Liabilities-to-Assets is 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Liabilities-to-Assets of 0.39. The current Liabilities-to-Assets is 0.39. Inmolecule Nanotech's overall GF Score™ is 7/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Liabilities-to-Assets is 0.39 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
7GF Score

Get the complete analysis for XPAR:MLINA

Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price